{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:42:37Z","timestamp":1782538957817,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100020170","name":"Research Nova Scotia","doi-asserted-by":"publisher","award":["1029591"],"award-info":[{"award-number":["1029591"]}],"id":[{"id":"10.13039\/501100020170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Proteom"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1186\/s12014-025-09560-6","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:24:21Z","timestamp":1761045861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel proteomic characterization of multiple myeloma bone marrow interstitial fluid links prognosis to coagulation pathways"],"prefix":"10.1186","volume":"22","author":[{"given":"Sam","family":"Cutler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Trottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Liwski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy","family":"Veinotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie St.","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Forward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"De La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Elnenaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"9560_CR1","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/cncr.32128","volume":"125","author":"M Tsang","year":"2019","unstructured":"Tsang M, Le M, Ghazawi FM, Cyr J, Alakel A, Rahme E, et al. Multiple myeloma epidemiology and patient geographic distribution in Canada: a population study. Cancer. 2019;125:2435\u201344.","journal-title":"Cancer"},{"key":"9560_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43:676\u201381.","journal-title":"Semin Oncol"},{"key":"9560_CR3","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4:1221.","journal-title":"JAMA Oncol"},{"key":"9560_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/nyas.13038","volume":"1364","author":"H Fairfield","year":"2016","unstructured":"Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016;1364:32\u201351.","journal-title":"Ann N Y Acad Sci"},{"key":"9560_CR5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet"},{"key":"9560_CR6","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122\u20138.","journal-title":"Leukemia"},{"key":"9560_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13083","volume":"101","author":"I Turesson","year":"2018","unstructured":"Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol. 2018;101:237\u201344.","journal-title":"Eur J Haematol"},{"key":"9560_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133337","volume":"15","author":"S Bowcock","year":"2023","unstructured":"Bowcock S, Atkin C, Iqbal G, Pratt G, Yong K, Neal RD, et al. Presenting symptoms in newly diagnosed myeloma, relation to organ damage, and implications for symptom-directed screening: a secondary analysis from the tackling early morbidity and mortality in myeloma (TEAMM) trial. Cancers (Basel). 2023;15:3337.","journal-title":"Cancers (Basel)"},{"key":"9560_CR9","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"9560_CR10","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"9560_CR11","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","volume":"102","author":"R Fonseca","year":"2003","unstructured":"Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102:2562\u20137.","journal-title":"Blood"},{"key":"9560_CR12","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-16-0867","volume":"22","author":"R Szalat","year":"2016","unstructured":"Szalat R, Avet-Loiseau H, Munshi NC. Gene expression profiles in myeloma: ready for the real world? Clin Cancer Res. 2016;22:5434\u201342.","journal-title":"Clin Cancer Res"},{"key":"9560_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1365-2362.1987.tb02197.x","volume":"17","author":"B Simonsson","year":"1987","unstructured":"Simonsson B, Brenning G, K\u00e4llander C, \u00c5hre A. Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma. Eur J Clin Invest. 1987;17:336\u20139.","journal-title":"Eur J Clin Invest"},{"key":"9560_CR14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/bjc.1980.273","volume":"42","author":"D Norfolk","year":"1980","unstructured":"Norfolk D, Child JA, Cooper EH, Kerruish S, Ward AM. Serum \u03b2 2-microglobulin in myelomatosis: potential value in stratification and monitoring. Br J Cancer. 1980;42:510\u20135.","journal-title":"Br J Cancer"},{"key":"9560_CR15","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/ejh.13325","volume":"103","author":"C Gran","year":"2019","unstructured":"Gran C, Uttervall K, Bruchfeld JB, Wallblom A, Alici E, Gahrton G, et al. Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration? Eur J Haematol. 2019;103:588\u201396.","journal-title":"Eur J Haematol"},{"key":"9560_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood.V59.1.43.43","volume":"59","author":"J Latreille","year":"1982","unstructured":"Latreille J, Barlogie B, Johnston D, Drewinko B, Alexanian R. Ploidy and proliferative characteristics in monoclonal gammopathies. Blood. 1982;59:43\u201351.","journal-title":"Blood"},{"key":"9560_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12014-023-09424-x","volume":"20","author":"AG Birhanu","year":"2023","unstructured":"Birhanu AG. Mass spectrometry-based proteomics as an emerging tool in clinical laboratories. Clin Proteom. 2023;20:32.","journal-title":"Clin Proteom"},{"key":"9560_CR18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2106053119","volume":"119","author":"S Ferdosi","year":"2022","unstructured":"Ferdosi S, Tangeysh B, Brown TR, Everley PA, Figa M, McLean M, et al. Engineered nanoparticles enable deep proteomics studies at scale by leveraging tunable nano\u2013bio interactions. Proc Natl Acad Sci U S A. 2022;119:e2106053119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9560_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202206008","volume":"34","author":"S Ferdosi","year":"2022","unstructured":"Ferdosi S, Stukalov A, Hasan M, Tangeysh B, Brown TR, Wang T, et al. Enhanced competition at the nano-bio interface enables comprehensive characterization of protein corona dynamics and deep coverage of proteomes. Adv Mater. 2022;34:2206008.","journal-title":"Adv Mater"},{"key":"9560_CR20","unstructured":"Siddiqui A. Large-scale, deep plasma proteomics: An 1800 sample study of Alzheimer\u2019s disease [Internet]. American Society of Mass Spectrometry; [cited 2023 June 29]. Available from: https:\/\/media.seer.bio\/uploads\/2023\/06\/2023_Poster_ASMS_Siddiqui.pdf"},{"key":"9560_CR21","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1038\/s41467-020-17033-7","volume":"11","author":"JE Blume","year":"2020","unstructured":"Blume JE, Manning WC, Troiano G, Hornburg D, Figa M, Hesterberg L, et al. Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona. Nat Commun. 2020;11:3662.","journal-title":"Nat Commun"},{"key":"9560_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.566804","volume":"10","author":"V Chanukuppa","year":"2021","unstructured":"Chanukuppa V, Taware R, Taunk K, Chatterjee T, Sharma S, Somasundaram V, et al. Proteomic alterations in multiple myeloma: a comprehensive study using bone marrow interstitial fluid and serum samples. Front Oncol. 2021;10:566804.","journal-title":"Front Oncol"},{"key":"9560_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153764","volume":"15","author":"K Dunphy","year":"2023","unstructured":"Dunphy K, Bazou D, Henry M, Meleady P, Miettinen JJ, Heckman CA, et al. Proteomic and metabolomic analysis of bone marrow and plasma from patients with extramedullary multiple myeloma identifies distinct protein and metabolite signatures. Cancers (Basel). 2023;15:3764.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"9560_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00784-3","volume":"5","author":"E Ramberger","year":"2024","unstructured":"Ramberger E, Sapozhnikova V, Ng YLD, Dolnik A, Ziehm M, Popp O, et al. The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities. Nat Cancer. 2024;5(8):1.","journal-title":"Nat Cancer"},{"key":"9560_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood-2023-189091","volume":"142","author":"ED Lightbody","year":"2023","unstructured":"Lightbody ED, Mani DR, Keshishian H, El-Khoury H, Dutta AK, Barr H, et al. High-throughput plasma proteomics to define the precursor multiple myeloma proteome and identify candidate high-risk disease biomarkers of progression. Blood. 2023;142:334.","journal-title":"Blood"},{"key":"9560_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227455","volume":"15","author":"A Mohamed","year":"2020","unstructured":"Mohamed A, Collins J, Jiang H, Molendijk J, Stoll T, Torta F, et al. Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: probing the lipid metabolome. PLoS ONE. 2020;15:e0227455.","journal-title":"PLoS ONE"},{"key":"9560_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278464","volume":"17","author":"D Apipongrat","year":"2022","unstructured":"Apipongrat D, Roytrakul S, Prayongratana K, Charoenpitakchai M, Intharanut K, Laoruangroj C, et al. Serum proteomic profiling reveals MTA2 and AGO2 as potential prognostic biomarkers associated with disease activity and adverse outcomes in multiple myeloma. PLoS ONE. 2022;17:e0278464.","journal-title":"PLoS ONE"},{"key":"9560_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31810-6","volume":"13","author":"ID Ferguson","year":"2022","unstructured":"Ferguson ID, Pati\u00f1o-Escobar B, Tuomivaara ST, Lin Y-HT, Nix MA, Leung KK, et al. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun. 2022;13:4121.","journal-title":"Nat Commun"},{"key":"9560_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/cge.13561","volume":"96","author":"MO Elnenaei","year":"2019","unstructured":"Elnenaei MO, Knopf P, Cutler SD, Sinclair K, Hassan MAE, Greer W, et al. Low-depth sequencing for copy number abnormalities in multiple myeloma supersedes fluorescent in situ hybridization in scope and resolution. Clin Genet. 2019;96:163\u20138.","journal-title":"Clin Genet"},{"key":"9560_CR30","unstructured":"Team RC. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria; 2018. Available from: https:\/\/www.R-project.org\/"},{"key":"9560_CR31","doi-asserted-by":"publisher","first-page":"D609","DOI":"10.1093\/nar\/gkae1010","volume":"53","author":"A Bateman","year":"2024","unstructured":"Consortium TU, Bateman A, Martin M-J, Orchard S, Magrane M, Adesina A, et al. UniProt: the Universal Protein Knowledgebase in 2025. Nucleic Acids Res. 2024;53:D609\u201317.","journal-title":"Nucleic Acids Res"},{"key":"9560_CR32","unstructured":"Li J, Bushel PR, Chu T, Wolfinger RD. 2009 Batch Effects and Noise in Microarray Experiments. Wiley Ser Probab Stat. 141\u201354."},{"key":"9560_CR33","unstructured":"Therneau TM. A package for survival analysis in R. 2024; Available from: https:\/\/CRAN.R-project.org\/package=survival"},{"key":"9560_CR34","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nprot.2017.147","volume":"13","author":"X Zhang","year":"2018","unstructured":"Zhang X, Smits AH, van Tilburg GB, Ovaa H, Huber W, Vermeulen M. Proteome-wide identification of ubiquitin interactions using UbIA-MS. Nat Protoc. 2018;13:530\u201350.","journal-title":"Nat Protoc"},{"key":"9560_CR35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang L-G, Han Y, He Q-Y. Clusterprofiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137.","journal-title":"OMICS"},{"key":"9560_CR36","doi-asserted-by":"crossref","unstructured":"Wickham H. ggplot2, Elegant Graphics for Data Analysis. 2nd ed. Springer-Verlag New York; 2016.","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"9560_CR37","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32:2847\u20139.","journal-title":"Bioinformatics"},{"key":"9560_CR38","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20130057","volume":"33","author":"LG Lima","year":"2013","unstructured":"Lima LG, Monteiro RQ. Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep. 2013;33:e00064.","journal-title":"Biosci Rep"},{"key":"9560_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41389-024-00522-5","volume":"13","author":"M Gao","year":"2024","unstructured":"Gao M, Dong H, Jiang S, Chen F, Fu Y, Luo Y. Activated platelet-derived exosomal LRG1 promotes multiple myeloma cell growth. Oncogenesis. 2024;13:21.","journal-title":"Oncogenesis"},{"key":"9560_CR40","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/hematology.2022000414","volume":"2022","author":"F Covut","year":"2022","unstructured":"Covut F, Sanfilippo KM. Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy. Hematology. 2022;2022:363\u20137.","journal-title":"Hematology"},{"key":"9560_CR41","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137:1959\u201369.","journal-title":"Blood"},{"key":"9560_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612563","volume":"24","author":"G Wilhelm","year":"2023","unstructured":"Wilhelm G, Mertowska P, Mertowski S, Przysucha A, Stru\u017cyna J, Grywalska E, et al. The crossroads of the coagulation system and the immune system: interactions and connections. Int J Mol Sci. 2023;24:12563.","journal-title":"Int J Mol Sci"},{"key":"9560_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/biology11040596","volume":"11","author":"L-QR Ling","year":"2022","unstructured":"Ling L-QR, Lin Z, Paolini R, Farah CS, McCullough M, Lim MAWT, et al. Commonly prescribed anticoagulants exert anticancer effects in oral squamous cell carcinoma cells in vitro. Biology. 2022;11:596.","journal-title":"Biology"},{"key":"9560_CR44","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2021","unstructured":"Perez-Riverol Y, Bai J, Bandla C, Garc\u00eda-Seisdedos D, Hewapathirana S, Kamatchinathan S, et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2021;50:D543\u201352.","journal-title":"Nucleic Acids Res"}],"container-title":["Clinical Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-025-09560-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12014-025-09560-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-025-09560-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:03:12Z","timestamp":1761091392000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalproteomicsjournal.biomedcentral.com\/articles\/10.1186\/s12014-025-09560-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9560"],"URL":"https:\/\/doi.org\/10.1186\/s12014-025-09560-6","relation":{},"ISSN":["1542-6416","1559-0275"],"issn-type":[{"value":"1542-6416","type":"print"},{"value":"1559-0275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Nova Scotia Health Research Ethics Board in accordance with the Declaration of Helsinki and institutional guidelines, and all participants provided written informed consent (REB # 1021397, 1022793 and 1021520).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}